Safety and tolerability study of AZD4831 in patients with heart failure. - SATELLITE

Study identifier:D6580C00003

ClinicalTrials.gov identifier:NCT03756285

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with preserved Ejection Fraction (HFpEF)

Medical condition

heart failure

Phase

Phase 2

Healthy volunteers

Study drug

AZD4831, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

45 Years - 85 Years

Date

Study Start Date: 11 Dec 2018

Primary Completion Date: 07 May 2020

Study Completion Date: 07 May 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2021 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

Informed consent
1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this CSP
2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses
Age
3. Patient must be 45 to 85 years of age inclusive, at the time of signing the informed consent form
Type of patient and disease characteristics
4. Signs and symptoms of HF in judgement of Investigator AND
a. Stable NYHA II-IV and
b. Ejection fraction (EF) ≥ 40 % and
c. Elevated NT-proBNP or BNP in the last 1 year defined as:
o Measured as out-patient: NT-proBNP ≥125 ng/L or BNP≥35 ng/L with sinus rhythm, NT-proBNP ≥750 ng/L or BNP ≥200 ng/L with atrial fibrillation (AF),
or
o Measured when hospitalized acutely: NT-proBNP ≥500 (ng/L) or BNP ≥125 ng/L with sinus rhythm, NT-proBNP ≥1250 (ng/L) or BNP ≥350 ng/L with AF
d. And at least one of the following:
• Hospitalization with HF as primary cause in last 12 months
• Structural heart disease on echo according to ESC guidelines i.e. either enlarged Left atrial volume index (LAVI > 34 ml/m2) or increased LVM (LVM index > 95 g/m2 in women and > 115 g/m2 in men)
• Pulmonary capillary wedge pressure (PCWP) at rest >15 mmHg or >25 mmHg at exercise
• Spectral tissue Doppler echocardiography - E/e’ ratio ≥13 at rest
Weight
5. Body Mass Index (BMI) range 18-40kg/m2
Sex
6. Male or female of nonchildbearing potential
Reproduction
7. Female patients must be 1 year post-menopausal or surgically sterile
8. Male patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of AZD4831/matching placebo to prevent pregnancy in a partner. Male patients must not donate or bank sperm during this same time period
Genetic sampling
9. For inclusion in this genetic research, patients must fulfil all of the inclusion criteria described above and provide informed consent for the genetic sampling and analysis

Exclusion Criteria

Creatinine clearance by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR <30 ml/min/1.73m2 or dialysis
Life expectancy < 3 years due to other reasons than cardiovascular disease
Any ongoing skin disorder, history of or ongoing clinically significant allergy/hypersensitivity.
Current decompensated HF
Primary cardiomyopathy (e.g. constrictive, restrictive, infiltrative, toxic, hypertrophic, congenital or any primary cardiomyopathy) in judgment of investigator
Current hemodynamically significant valve disease in opinion of investigator
EF ever documented < 40%
Any current life-threatening dysrhythmia
Probable alternative primary reason for patient’s symptoms in judgment of investigator, including but not limited to:
a. Isolated pulmonary arterial hypertension or right ventricular (RV) failure; in the absence of left-sided HF
b. Anaemia: Hb <100 mg/L (10g/dL)
c. Severe chronic obstructive pulmonary disease (COPD) or lung disease (chronic O2, nebulizer or oral steroid therapy)
Cardiac surgery, acute coronary syndrome (ACS), or non-elective percutaneous coronary intervention (PCI) < 3 months
Known or clinically judged significant macrovascular coronary artery disease (CAD) that has not been revascularized
Heart transplantation or left ventricular assist device ever
Patients with uncontrolled or clinically significant thyroid disease as judged by the investigator.
Alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥2 x upper limit of normal (ULN). Resampling will not be allowed during the same screening period if detected abnormal values do not have reasonable explanation and are not expected to return to normal level within few days.
Known positive HIV, hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening

No locations available

Arms	Assigned Interventions
Experimental: AZD4831 AZD4831 tablets taken orally for for 90 days.	Drug: AZD4831 AZD4831 tablet taken orally for 90 days.
Placebo Comparator: Placebo Placebo tablets taken orally for 90 days.	Drug: Placebo Placebo tablet taken orally for 90 days.

Documents available

Redacted CSP
Download
Redacted SAP
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]